Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
CALA is in the long-term down -55% below S&P in 3 years.
Description: Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.
|Shares Outstanding||EPS||-1.66||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-8.67|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-20.57%||ROE||-21.41%||ROI|
|Current Ratio||25.65||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.04|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||10 K||Cash From Investing Activities||-20.47 M||Cash From Operating Activities||-7.63 M||Gross Profit|
|Net Profit||-7.86 M||Operating Profit||-7.87 M||Total Assets||96.87 M||Total Current Assets||90.31 M|
|Total Current Liabilities||3.52 M||Total Debt||Total Liabilities||3.77 M||Total Revenue|
|High 52 week||9.05||Low 52 week||4.08||Last close||5.64||Last change||-1.4%|
|RSI||34||Average true range||0.32||Beta||1.56||Volume||180.6 K|
|Simple moving average 20 days||-6.72%||Simple moving average 50 days||-10.43%||Simple moving average 200 days||1.68%|
|Performance Week||-6.93%||Performance Month||-7.54%||Performance Quart||5.22%||Performance Half||7.43%|
|Performance Year||-32.46%||Performance Year-to-date||25.33%||Volatility daily||2.73%||Volatility weekly||6.09%|
|Volatility monthly||12.49%||Volatility yearly||43.26%||Relative Volume||2060.39%||Average Volume||172.05 K|
|New High||New Low|
2019-08-23 09:11:52 | Is Calithera Biosciences, Inc.'s NASDAQ:CALA CEO Pay Justified?
2019-08-10 09:57:34 | Edited Transcript of CALA earnings conference call or presentation 8-Aug-19 9:00pm GMT
2019-07-24 10:40:51 | Does Calithera Biosciences, Inc. NASDAQ:CALA Have A High Beta?
2019-06-18 23:00:00 | Calithera Biosciences, Inc. Prices Public Offering of 12,500,000 shares of Common Stock
2019-06-18 13:16:37 | Did You Miss Calithera Biosciences's NASDAQ:CALA 37% Share Price Gain?
2019-06-17 10:04:42 | Calithera's Kidney Cancer Drug Doubles Progression-Free Survival Vs. Chemotherapy
2019-05-14 12:34:47 | Calithera Biosciences, Inc. CALA Q1 2019 Earnings Call Transcript
2019-05-10 18:08:28 | Edited Transcript of CALA earnings conference call or presentation 9-May-19 9:00pm GMT
2019-05-10 05:14:17 | Calithera: 1Q Earnings Snapshot
2019-05-09 16:06:00 | Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights
2019-05-02 10:32:02 | Analysts Estimate Calithera CALA to Report a Decline in Earnings: What to Look Out for
2019-04-25 07:34:54 | How Many Calithera Biosciences, Inc. NASDAQ:CALA Shares Do Institutions Own?
2019-03-27 17:39:09 | Calithera CALA Initiates Phase I/II Study of Telaglenastat
2019-03-07 20:40:17 | Edited Transcript of CALA earnings conference call or presentation 7-Mar-19 9:30pm GMT
2019-03-05 07:05:00 | Calithera to Present at Cowen & Company 39th Annual Healthcare Conference
2019-02-22 08:00:00 | Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
2019-01-28 07:30:00 | Analysis: Positioning to Benefit within Rollins, Hospitality Properties Trust, Exact Sciences, Tenet Healthcare, Entergy, and Calithera Biosciences — Research Highlights Growth, Revenue, and Consolidated Results
2019-01-18 14:19:35 | What Did Calithera Biosciences, Inc.’s NASDAQ:CALA CEO Take Home Last Year?
2018-11-30 08:00:00 | Calithera Biosciences to Participate in the 2018 Citi Global Healthcare Conference
2018-11-09 08:10:00 | New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences — Factors of Influence, Major Initiatives and Sustained Production
2018-11-08 07:11:14 | Edited Transcript of CALA earnings conference call or presentation 7-Nov-18 10:00pm GMT
2018-11-07 20:35:01 | Calithera CALA Reports Q3 Loss, Lags Revenue Estimates
2018-11-07 19:32:17 | Calithera: 3Q Earnings Snapshot
2018-11-07 16:05:00 | Calithera Biosciences Reports Third Quarter 2018 Financial Results and Recent Highlights
2018-10-15 08:55:00 | Market Trends Toward New Normal in Nasdaq, Calithera Biosciences, Pinnacle West Capital, National Instruments, American Vanguard, and American Axle & Manufacturing — Emerging Consolidated Expectations, Analyst Ratings
2018-10-05 07:01:00 | Calithera Biosciences Highlights Breadth of Innovative Pipeline at R&D Day
2018-09-26 08:00:00 | Calithera Biosciences to Host R&D Day and Webcast on October 5, 2018